ArticleClinics (Sao Paulo, Brazil)2025
Predictive value of serum chitinase 3-like 1 for dysfunctional autogenous arteriovenous fistulas in patients with chronic kidney disease stage G5.
Article in Clinics (Sao Paulo, Brazil), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveArteriovenous Fistula (AVF) is the preferred vascular access for patients with Chronic Kidney Disease Stage G5 (CKDG5). Normal AVF function is an important prerequisite for hemodialysis, and there are few reports of studies predicting the factors affecting dysfunctional AVF. The aim of this study was to investigate the expression of Chitosanase-3-Like protein-1 (CHI3L1) in AVFs from patients with end-stage renal disease and to analyze the potential mechanism of its role in AVF dysfunction.
methodsCKDG5 patients who underwent AVF surgery at our institution from January 2020 to September 2023 were prospectively collected. The general clinical data and laboratory data were collected in detail, and the occurrence of postoperative dysfunctional AVF was recorded. Then, the optimal diagnostic threshold of serum CHI3L1 was observed by the Receiver Operating Characteristic (ROC) curve. Kaplan-Meier survival curve and Log-rank test were used for survival analysis. Multi-factor backward logic analysis was used to screen baseline clinical factors and construct prediction Model 1. Subsequently, serum CHI3L1 was combined with baseline clinical factors to construct Prediction Model 2. The predictive value of the two models was evaluated by the ROC curve and the Area Under the Curve (AUC).
resultsA total of 152 CKDG5 patients who underwent AVF surgery were continuously included. They were divided into a normal AVF group (n = 64) and a dysfunctional AVF group (n = 88). Gender, age, body mass index, primary disease, diameter of cephalic vein, diameter of radial artery, follow-up time, and levels of Ca, K, total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein, white blood cell count, platelets, fasting blood glucose, and hemoglobin in both groups were not statistically significant between the two groups (p > 0.05). Systolic blood pressure, diastolic blood pressure, parathyroid hormone, serum albumin, and CHI3L1 were increased, whereas serum phosphorus level was decreased in CKDG5 patients with dysfunctional AVF (p < 0.05). The AUC of serum CHI3L1 was 0.797 (95% CI 0.728‒0.866, p < 0.001), the optimal cut-off value was 148.0 ng/mL, the sensitivity was 62.5%, and the specificity was 84.38%. The primary fluency rate in the high serum CHI3L1 level group was significantly lower than that in the low serum CHI3L1 level group (p < 0.001). Multifactorial logistic regression analysis showed that elevated serum CHI3L1 was an independent risk factor for postoperative dysfunctional AVF. The predictive value of the CHI3L1-containing predictive Model 2 was higher, with a net benefit at threshold probabilities of 0.2‒0.9 for its clinical decision curve.
conclusionThis study proposes a risk prediction model of serum CHI3L1 combined with clinical risk factors, which can be utilized to make a preliminary prediction of the risk of dysfunctional AVF more easily, and thereafter to identify and intervene in high-risk patients early.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.